Cargando…

VEGF: From Discovery to Therapy: The Champalimaud Award Lecture

PURPOSE: Intraocular vascular diseases are leading causes of adult vision loss, and in the mid-1900s, I. C. Michaelson postulated that the retina releases a soluble, diffusible factor that causes abnormal vascular growth and leakage. What became known as “Factor X” eluded investigators for decades....

Descripción completa

Detalles Bibliográficos
Autor principal: Miller, Joan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790434/
https://www.ncbi.nlm.nih.gov/pubmed/26981331
http://dx.doi.org/10.1167/tvst.5.2.9
_version_ 1782420992758382592
author Miller, Joan W.
author_facet Miller, Joan W.
author_sort Miller, Joan W.
collection PubMed
description PURPOSE: Intraocular vascular diseases are leading causes of adult vision loss, and in the mid-1900s, I. C. Michaelson postulated that the retina releases a soluble, diffusible factor that causes abnormal vascular growth and leakage. What became known as “Factor X” eluded investigators for decades. METHODS: The field of cancer research, where Judah Folkman pioneered the concept of angiogenesis, provided the inspiration for the work honored by the 2014 Champalimaud Vision Award. Recognizing that tumors recruit their own blood supply to achieve critical mass, Dr Folkman proposed that angiogenic factors could be therapeutic targets in cancer. Napoleone Ferrara identified vascular endothelial growth factor (VEGF) as such an angiogenic agent: stimulated by hypoxic tumor tissue, secreted, and able to induce neovascularization. VEGF also was a candidate for Factor X, and the 2014 Champalimaud Laureates and colleagues worked individually and collaboratively to identify the role of VEGF in ocular disease. RESULTS: The Champalimaud Laureates correlated VEGF with ocular neovascularization in animal models and in patients. Moreover, they showed that VEGF not only was sufficient, but it also was required to induce neovascularization in normal animal eyes, as VEGF inhibition abolished ocular neovascularization in key animal models. CONCLUSIONS: The identification of VEGF as Factor X altered the therapeutic paradigms for age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and other retinal disorders. TRANSLATIONAL RELEVANCE: The translation of VEGF from discovery to therapy resulted in the most successful applications of antiangiogenic therapy to date. Annually, over one million patients with eye disease are treated with anti-VEGF agents.
format Online
Article
Text
id pubmed-4790434
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-47904342016-03-15 VEGF: From Discovery to Therapy: The Champalimaud Award Lecture Miller, Joan W. Transl Vis Sci Technol Perspective PURPOSE: Intraocular vascular diseases are leading causes of adult vision loss, and in the mid-1900s, I. C. Michaelson postulated that the retina releases a soluble, diffusible factor that causes abnormal vascular growth and leakage. What became known as “Factor X” eluded investigators for decades. METHODS: The field of cancer research, where Judah Folkman pioneered the concept of angiogenesis, provided the inspiration for the work honored by the 2014 Champalimaud Vision Award. Recognizing that tumors recruit their own blood supply to achieve critical mass, Dr Folkman proposed that angiogenic factors could be therapeutic targets in cancer. Napoleone Ferrara identified vascular endothelial growth factor (VEGF) as such an angiogenic agent: stimulated by hypoxic tumor tissue, secreted, and able to induce neovascularization. VEGF also was a candidate for Factor X, and the 2014 Champalimaud Laureates and colleagues worked individually and collaboratively to identify the role of VEGF in ocular disease. RESULTS: The Champalimaud Laureates correlated VEGF with ocular neovascularization in animal models and in patients. Moreover, they showed that VEGF not only was sufficient, but it also was required to induce neovascularization in normal animal eyes, as VEGF inhibition abolished ocular neovascularization in key animal models. CONCLUSIONS: The identification of VEGF as Factor X altered the therapeutic paradigms for age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and other retinal disorders. TRANSLATIONAL RELEVANCE: The translation of VEGF from discovery to therapy resulted in the most successful applications of antiangiogenic therapy to date. Annually, over one million patients with eye disease are treated with anti-VEGF agents. The Association for Research in Vision and Ophthalmology 2016-03-11 /pmc/articles/PMC4790434/ /pubmed/26981331 http://dx.doi.org/10.1167/tvst.5.2.9 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Perspective
Miller, Joan W.
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title_full VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title_fullStr VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title_full_unstemmed VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title_short VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
title_sort vegf: from discovery to therapy: the champalimaud award lecture
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790434/
https://www.ncbi.nlm.nih.gov/pubmed/26981331
http://dx.doi.org/10.1167/tvst.5.2.9
work_keys_str_mv AT millerjoanw vegffromdiscoverytotherapythechampalimaudawardlecture